ESR1 and breast carcinoma: Biannual screening is recommended for women aged 40 to 74 years by the US Preventive Services Task Force (USPSTF),1 as it has been shown to reduce the mortality associated with estrogen receptor–positive (ER+) breast cancer and the incidence of late-stage diagnosis.2